Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Design
  4. Volume 28, Issue 45
  5. Article
Volume 28, Issue 45
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The cytochrome P450 enzymes play a significant role in regulating cellular and physiological processes by activating endogenous compounds. They also play an essential role in the detoxification process of xenobiotics. Flavonoids belong to a class of polyphenols found in food, such as vegetables, red wine, beer, and fruits, which modulate biological functions in the body.

The inhibition of CYP1A1 and CYP1B1 using nutritional sources has been reported as a strategy for cancer prevention. This study investigated the interactions of selected flavonoids binding to the cytochrome P450 enzymes (CYP1A1 and CYP1B1) and their ADMET properties . From docking studies, our findings showed flavonoids, isorhamnetin and pedalitin, to have the strongest binding energies in the crystal structures 6DWM and 6IQ5.

The amino acid residues Asp 313 and Phe 224 in 6DWM interacted with all the ligands investigated, and Ala 330 in 6IQ5 interacted with all the ligands examined. The ligands did not violate any drug-likeness parameters.

These data suggest roles for isorhamnetin and pedalitin as potential precursors for natural product-derived therapies.

© 2022 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612829666221121151713
2022-01-01
2024-10-09

  • From This Site

    /content/journals/cpd/10.2174/1381612829666221121151713
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Urban P. Lautier T. Pompon D. Truan G. Ligand access channels in cytochrome P450 enzymes: A review. Int. J. Mol. Sci. 2018 19 6 1617 10.3390/ijms19061617 29848998
    [Google Scholar]
  2. Manikandan P. Nagini S. Cytochrome P450 structure, function and clinical significance: A review. Curr. Drug Targets 2018 19 1 38 54 10.2174/1389450118666170125144557 28124606
    [Google Scholar]
  3. Androutsopoulos V.P. Papakyriakou A. Vourloumis D. Spandidos D.A. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids. Bioorg. Med. Chem. 2011 19 9 2842 2849 10.1016/j.bmc.2011.03.042 21482471
    [Google Scholar]
  4. Zhang H. Li L. Xu Y. CYP1B1 polymorphisms and susceptibility to prostate cancer: A meta-analysis. PLoS One 2013 8 7 e68634 10.1371/journal.pone.0068634 23861929
    [Google Scholar]
  5. Min L. Tang J. Tong A. Mu X. Yang Y. Yi T. Zhao X. Cytochrome P450 1B1 Leu432val gene polymorphisms in the risks of benign uterine diseases: A systemic review and meta-analysis. Int. J. Clin. Exp. Med. 2017 10 8780 8787
    [Google Scholar]
  6. Wongpratate M. Ishida W. Phuthong S. Natphopsuk S. Ishida T. Genetic polymorphisms of the human cytochrome P450 1A1 (CYP1A1) and cervical cancer susceptibility among Northeast Thai women. Asian Pac. J. Cancer Prev. 2020 21 1 243 248 10.31557/APJCP.2020.21.1.243 31983191
    [Google Scholar]
  7. Santes-Palacios R. Marroquín-Pérez A.L. Hernández-Ojeda S.L. Camacho-Carranza R. Govezensky T. Espinosa-Aguirre J.J. Human CYP1A1 inhibition by flavonoids. Toxicol. In Vitro 2020 62 104681 10.1016/j.tiv.2019.104681 31655123
    [Google Scholar]
  8. Zhai S. Dai R. Friedman F.K. Vestal R.E. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab. Dispos. 1998 26 10 989 992 9763404
    [Google Scholar]
  9. Androutsopoulos V.P. Tsatsakis A.M. Spandidos D.A. Cytochrome P450 CYP1A1: Wider roles in cancer progression and prevention. BMC Cancer 2009 9 1 187 10.1186/1471‑2407‑9‑187 19531241
    [Google Scholar]
  10. Dong J. Wang N.N. Yao Z.J. Zhang L. Cheng Y. Ouyang D. Lu A.P. Cao D.S. ADMETlab: A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. J. Cheminform. 2018 10 1 29 29 10.1186/s13321‑018‑0283‑x 29943074
    [Google Scholar]
  11. van de Waterbeemd H. Gifford E. ADMET in silico modelling: Towards prediction paradise? Nat. Rev. Drug Discov. 2003 2 3 192 204 10.1038/nrd1032 12612645
    [Google Scholar]
  12. Bart A.G. Scott E.E. Structures of human cytochrome P450 1A1 with bergamottin and erlotinib reveal active-site modifications for binding of diverse ligands. J. Biol. Chem. 2018 293 50 19201 19210 10.1074/jbc.RA118.005588 30254074
    [Google Scholar]
  13. Kubo M. Yamamoto K. Itoh T. Design and synthesis of selective CYP1B1 inhibitor via dearomatization of α-naphthoflavone. Bioorg. Med. Chem. 2019 27 2 285 304 10.1016/j.bmc.2018.11.045 30553624
    [Google Scholar]
  14. Briguglio M. Hrelia S. Malaguti M. Serpe L. Canaparo R. Dell’Osso B. Galentino R. De Michele S. Dina C.Z. Porta M. Banfi G. Food bioactive compounds and their interference in drug pharmacokinetic/pharmacodynamic profiles. Pharmaceutics 2018 10 4 277 10.3390/pharmaceutics10040277 30558213
    [Google Scholar]
  15. Sergent T. Dupont I. Van Der Heiden E. Scippo M.L. Pussemier L. Larondelle Y. Schneider Y.J. CYP1A1 and CYP3A4 modulation by dietary flavonoids in human intestinal caco-2 cells. Toxicol. Lett. 2009 191 2-3 216 222 10.1016/j.toxlet.2009.09.002 19766177
    [Google Scholar]
  16. Takemura H. Itoh T. Yamamoto K. Sakakibara H. Shimoi K. Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg. Med. Chem. 2010 18 17 6310 6315 10.1016/j.bmc.2010.07.020 20696580
    [Google Scholar]
  17. Androutsopoulos V. Arroo R.R.J. Hall J.F. Surichan S. Potter G.A. Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1-mediated metabolism. Breast Cancer Res. 2008 10 3 R39 10.1186/bcr2090 18454852
    [Google Scholar]
  18. Patel D.K. Biological potential and therapeutic benefit of chrysosplenetin: An applications of polymethoxylated flavonoid in medicine from natural sources. Pharmacol Res Mod Chin Med 2022 4 100155 10.1016/j.prmcm.2022.100155
    [Google Scholar]
  19. Stroganov O.V. Novikov F.N. Stroylov V.S. Kulkov V. Chilov G.G. Lead finder: An approach to improve accuracy of protein-ligand docking, binding energy estimation, and virtual screening. J. Chem. Inf. Model. 2008 48 12 2371 2385 10.1021/ci800166p 19007114
    [Google Scholar]
  20. Novikov F.N. Stroylov V.S. Zeifman A.A. Stroganov O.V. Kulkov V. Chilov G.G. Lead Finder docking and virtual screening evaluation with Astex and DUD test sets. J. Comput. Aided Mol. Des. 2012 26 6 725 735 10.1007/s10822‑012‑9549‑y 22569592
    [Google Scholar]
  21. Walsh A.A. Szklarz G.D. Scott E.E. Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J. Biol. Chem. 2013 288 18 12932 12943 10.1074/jbc.M113.452953 23508959
    [Google Scholar]
  22. Dutkiewicz Z. Mikstacka R. Structure-based drug design for cytochrome P450 family 1 inhibitors. Bioinorg. Chem. Appl. 2018 2018 1 21 10.1155/2018/3924608 30147715
    [Google Scholar]
  23. Mikstacka R. Dutkiewicz Z. New perspectives of CYP1B1 inhibitors in the light of molecular studies. Processes 2021 9 5 817 10.3390/pr9050817
    [Google Scholar]
  24. Juvonen R.O. Ahinko M. Jokinen E.M. Huuskonen J. Raunio H. Pentikäinen O.T. Substrate selectivity of coumarin derivatives by human CYP1 enzymes: In vitro enzyme kinetics and in silico modeling. ACS Omega 2021 6 17 11286 11296 10.1021/acsomega.1c00123 34056284
    [Google Scholar]
  25. Lee J.Y. Cho H. Thangapandian S. Lim C. Chun Y.J. Lee Y. Choi S. Kim S. Adaptable small ligand of CYP1 enzymes for use in understanding the structural features determining isoform selectivity. ACS Med. Chem. Lett. 2018 9 12 1247 1252 10.1021/acsmedchemlett.8b00409 30613334
    [Google Scholar]
  26. Raju B. Narendra G. Verma H. Kumar M. Sapra B. Kaur G. jain S.K. Silakari O. Machine learning enabled structure-based drug repurposing approach to identify potential CYP1B1 inhibitors. ACS Omega 2022 7 36 31999 32013 10.1021/acsomega.2c02983 36120033
    [Google Scholar]
  27. McGraw J. CYP450 and Ethnicity. Handbook of Pharmacogenomics and Stratified Medicine. San Diego: Academic Press Padmanabhan S. 2014 323 340 10.1016/B978‑0‑12‑386882‑4.00016‑5
    [Google Scholar]
  28. Vishwanath Gaitonde P.K.A.T. Molecular Docking in Modern Drug Discovery: Principles and Recent Applications. Drug Discovery and Development - New Advances. IntechOpen 2019
    [Google Scholar]
  29. Cresset® Flare, 2.0. Litlington, Cambridgeshire 2019.
  30. Sehgal S. Tahir A. Shafique S. Hassan M. Rashid S. Molecular modeling and docking analysis of CYP1A1 associated with head and neck cancer to explore its binding regions. Theor. Comput. Sci. 2014 1
    [Google Scholar]
  31. Santes-Palacios R. Ornelas-Ayala D. Cabañas N. Marroquín-Pérez A. Hernández-Magaña A. del Rosario Olguín-Reyes S. Camacho-Carranza R. Espinosa-Aguirre J.J. Regulation of human cytochrome P4501A1 (hCYP1A1): A plausible target for chemoprevention? BioMed Res. Int. 2016 2016 1 17 10.1155/2016/5341081 28105425
    [Google Scholar]
  32. Scotti L. Bezerra Mendonça Junior F.J. Magalhaes Moreira D.R. da Silva M.S. Pitta I.R. Scotti M.T. SAR, QSAR and docking of anticancer flavonoids and variants: a review. Curr. Top. Med. Chem. 2012 12 24 2785 2809 10.2174/1568026611212240007 23368103
    [Google Scholar]
  33. Daina A. Michielin O. Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017 7 1 42717 10.1038/srep42717 28256516
    [Google Scholar]
  34. Teague S.J. Davis A.M. Leeson P.D. Oprea T. The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. 1999 38 24 3743 3748 10.1002/(SICI)1521‑3773(19991216)38:24<3743::AID‑ANIE3743>3.0.CO;2‑U 10649345
    [Google Scholar]
  35. Guan L. Yang H. Cai Y. Sun L. Di P. Li W. Liu G. Tang Y. ADMET-score – a comprehensive scoring function for evaluation of chemical drug-likeness. MedChemComm 2019 10 1 148 157 10.1039/C8MD00472B 30774861
    [Google Scholar]
  36. Kumar S.A. Bhaskar B.L. Computational and spectral studies of 3,3′-(propane-1,3-diyl)bis(7,8-dimethoxy-1,3,4,5-tetrahydro-2H- benzo[d]azepin-2-one). Heliyon 2019 5 9 e02420 10.1016/j.heliyon.2019.e02420 31687545
    [Google Scholar]
  37. Cournia Z. Allen B. Sherman W. Relative binding free energy calculations in drug discovery: Recent advances and practical considerations. J. Chem. Inf. Model. 2017 57 12 2911 2937 10.1021/acs.jcim.7b00564 29243483
    [Google Scholar]
/content/journals/cpd/10.2174/1381612829666221121151713
Loading
Computational Investigation of Ligand Binding of Flavonoids in Cytochrome P450 Receptors
Curr. Pharm. Des. 28, 3637; https://doi.org/10.2174/1381612829666221121151713
/content/journals/cpd/10.2174/1381612829666221121151713
/content/journals/cpd/10.2174/1381612829666221121151713
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): ADMET; CYP1A1; CYP1B1; cytochrome P450; Flavone; ligand docking

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test